“Ahead of the pending Phase 3 results for UX007 (trihep) in Glut1 DS expected sometime this quarter, we sifted through early data and market sizing assumptions to frame expectations and potential upside/downside on the event. Bottom line, while directly comparable data are limited to say the least (most similar pilot study only had an N of 6 and Phase 2 trials evaluated different endpoints), we believe a positive read- out is the most likely outcome given proof of concept data combined with seemingly reasonable powering assumptions. Between the recent pullback in shares (15% since 9/25) and our sense that this opportunity is not well understood by the market, we see risk/reward slightly skewed to the upside. Maintain OW.”
According to TipRanks.com, Kasimov is a 3-star analyst with an average return of 2.7% and a 40.9% success rate. Kasimov covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Jounce Therapeutics Inc, and Acorda Therapeutics.
Ultragenyx has an analyst consensus of Strong Buy, with a price target consensus of $91.36, a 23.2% upside from current levels. In a report issued on September 27, Cowen & Co. also maintained a Buy rating on the stock.
Based on Ultragenyx’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $52.73 million. In comparison, last year the company had a GAAP net loss of $79.23 million.
Based on the recent corporate insider activity of 57 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita.